Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Cancer Res. 2017 Apr 12;77(11):2927–2937. doi: 10.1158/0008-5472.CAN-16-3351

Figure 2.

Figure 2

Gene expression profiles of eMC expressing CIC-DUX4 and mCDS tumors. A, Venn diagram showing upregulated genes in eMC expressing CIC-DUX4 (n = 4) or mCDS tumors (n = 6) vs those containing an empty vector (n = 4). B, GSEA of eMC expressing CIC-DUX4 versus those with an empty vector shows enrichment of the gene set involved in ECM organization (left), and mCDS tumors versus eMC with an empty vector shows the Cyclin D1 pathway (right). C, Principal component analysis for gene expression profiles of mCDS and mES. D, Hierarchical clustering with 1,661 differentially upregulated genes in mCDS or mES. E, Real-time quantitative RT-PCR for Ccnd1, Ccnd2, Bcl2, Ret, Muc5ac and Etv4 in 6 independent mCDS and mES tumors, eMC with an empty vector and the CIC-DUX4 retrovirus. F, GSEA shows enrichment of the VEGF signaling pathway and the Cyclin D1 signature in mCDS. G, Hierarchical clustering of gene expression profiles of 6 samples of mCDS, 5 cases of hCDS, 20 myxoid liposarcomas (MLS), 21 malignant fibrous histiocytomas (MFH), 16 synovial sarcomas (SS), 11 osteosarcomas (OS), 7 chondrosarcomas (CS), 32 Ewing sarcomas (ES) and 10 neuroblastomas (NB).